New potential drug target for Alzheimer’s disease identified

New potential drug target for Alzheimer’s disease identified

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Studying protein-sugar interaction proved to be a sweet success for researchers.

Recent research has shed light on the interactions between Apolipoprotein E (ApoE) and heparan sulfate (HS), uncovering potential therapeutic targets to slow the progression of the debilitating neurodegenerative disease Alzheimer’s. A new study published in Angewandte Chemie, Chunyu Wang, PhD, professor of biological sciences at Rensselaer Polytechnic Institute, and his team have made significant strides in understanding the mechanisms underlying Alzheimer’s disease [1].

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE